Articles by Julie Gould
Researchers at the 2024 American Society of Hematology Annual Meeting said follicular lymphoma is biologically diverse.
The evolving role of HSCT aAHSCT, and allo-HSCT requires further clarification amid new treatment advances in WM.
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Treatment choice significantly influences outcomes in patients with mantle cell lymphoma.
The efficacy of HSCT for FL and provides a benchmark for testing emerging therapies like CAR-T and bispecific antibodies.
Researchers generated Patient-Derived Lymphoma Tumoroids to replicate the FL tumor microenvironment.
Researchers at ASH 2024 explained that adolescents and young adults with non-Hodgkin lymphoma face fertility challenges.
Future studies should explore combining allo-HSCT with novel therapies to enhance outcomes further.
The functional and structural relevance of IGHV1-204 remains unclear for patients with splenic marginal zone lymphoma.
A retrospective analysis observed 3,897 patients with lymphoma enrolled in 32 cooperative group trials between 2005 and 2020.
Marginal zone lymphoma lacks extensive research on its real-world treatment patterns and economic impact.
Patients with follicular lymphoma and early progression are a distinctly vulnerable population who need further study.
A study stresses psychological support as an essential component of comprehensive cancer care.
Good local control over five years using a very low dose approach was possible for potentially curable patients.
A phase I/II first-in-human study evaluates a new bivalent small molecule in relapsed or refractory FL and MZL.
Study investigated if high Vulnerable Elders Survey scores were associated with changes in quality of life across age groups.
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.